Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Moderna, Inc. (MRNA : NSDQ)
 
 • Company Description   
Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.

Number of Employees: 5,800

 
 • Price / Volume Information   
Yesterday's Closing Price: $34.28 Daily Weekly Monthly
20 Day Moving Average: 9,222,445 shares
Shares Outstanding: 386.74 (millions)
Market Capitalization: $13,257.51 (millions)
Beta: 1.84
52 Week High: $129.39
52 Week Low: $23.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 25.34% 20.64%
12 Week 38.70% 16.67%
Year To Date -17.56% -22.79%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
325 BINNEY STREET
-
CAMBRIDGE,MA 02142
USA		 ph: 617-714-6500
fax: -		 ir@modernatx.com http://www.modernatx.com
 
 • General Corporate Information   
Officers
Stephane Bancel - Chief Executive Officer
Noubar B. Afeyan - Chairman
James M. Mock - Chief Financial Officer
Sandra Horning - Director
Abbas Hussain - Director

Peer Information
Moderna, Inc. (CORR.)
Moderna, Inc. (RSPI)
Moderna, Inc. (CGXP)
Moderna, Inc. (BGEN)
Moderna, Inc. (GTBP)
Moderna, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 60770K107
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 386.74
Most Recent Split Date: (:1)
Beta: 1.84
Market Capitalization: $13,257.51 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.85 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-9.81 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 22.11% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.32
Price/Cash Flow: -
Price / Sales: 4.17
EPS Growth
vs. Year Ago Period: 17.92%
vs. Previous Quarter: -0.80%
Sales Growth
vs. Year Ago Period: -35.33%
vs. Previous Quarter: -88.82%
ROE
06/30/25 - -
03/31/25 - -28.69
12/31/24 - -28.74
ROA
06/30/25 - -
03/31/25 - -21.94
12/31/24 - -21.83
Current Ratio
06/30/25 - -
03/31/25 - 4.22
12/31/24 - 3.67
Quick Ratio
06/30/25 - -
03/31/25 - 4.14
12/31/24 - 3.62
Operating Margin
06/30/25 - -
03/31/25 - -100.69
12/31/24 - -105.16
Net Margin
06/30/25 - -
03/31/25 - -105.67
12/31/24 - -110.04
Pre-Tax Margin
06/30/25 - -
03/31/25 - -107.21
12/31/24 - -111.46
Book Value
06/30/25 - -
03/31/25 - 26.03
12/31/24 - 28.33
Inventory Turnover
06/30/25 - -
03/31/25 - 5.52
12/31/24 - 4.79
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.35
12/31/24 - 0.36
 

Powered by Zacks Investment Research ©